Health Topics – Johns Hopkins Medicine Podcasts

A new blood test for Alzheimer’s disease isn’t a stand alone diagnostic tool. That’s according to Abhay Moghekar, a blood biomarkers expert and a neurologist at Johns Hopkins. Moghekar: You would still need the clinical input in the context of …

A truly comprehensive test for Alzheimer’s disease may be on the horizon, Elizabeth Tracey reports Read more →

Will an FDA cleared blood test for Alzheimer’s disease ease or complicate diagnosis? Clearly in approving the test the FDA hopes for the former, yet the complete picture is more complex than that, says Abhay Moghekar, a blood biomarkers expert …

Biomarkers alone don’t mean Alzheimer’s disease is present, Elizabeth Tracey reports Read more →

Positive results on the newly FDA cleared blood test for Alzheimer’s disease don’t necessarily mean you have the disease. That’s according to blood biomarkers expert Abhay Moghekar, a neurologist at Johns Hopkins. Moghekar: Whether that's the cause of your cognitive …

If you get a positive result on the new blood test for Alzheimer’s disease, what does that mean? Elizabeth Tracey reports Read more →

The FDA has just cleared a blood test to help make the diagnosis of Alzheimer’s disease, which otherwise may require some fairly invasive methods. Blood biomarkers expert Abhay Moghekar, a neurologist at Johns Hopkins, says the test looks for the …

Who is a candidate for the new blood test for Alzheimer’s disease? Elizabeth Tracey reports Read more →

A blood test to screen for proteins related to Alzheimer’s disease has been cleared by the FDA, and it’s designed for people who are older than 55 years of age and have cognitive symptoms. Johns Hopkins neurologist Abhay Moghekar, a …

What’s the basis of the new blood test to screen for Alzheimer’s disease? Elizabeth Tracey reports Read more →

NPTX2 is a protein that’s pivotal for helping your brain decide to remember certain things and forget others, and when levels of it decline it suggests that neurodegenerative processes like dementia may be beginning. That’s according to research by Paul …

A protein that’s made in your brain at night helps you remember things, Elizabeth Tracey reports Read more →

Many theories on how brain disorders like Alzheimer’s disease begin point to proteins called amyloid beta and tau as accumulating and disrupting the function of neurons. Research by neuroscientist Paul Worley and colleagues at Johns Hopkins points to declining levels …

How do neurodegenerative diseases begin? Elizabeth Tracey reports Read more →

You probably know how complex your brain function is, relying on a delicately balanced system full of proteins that act as signals and specialized nerve and structural cells. Turns out there is an interplay of some neurons being shut down …

A change in a protein in the brain signals possible neurocognitive disorders, Elizabeth Tracey reports Read more →

NPTX2 is the abbreviation for a protein found in the brain that may allow much more accurate prognosis of who’s at risk for developing neurocognitive disorders, including Alzheimer’s disease and other dementias. That’s according to Johns Hopkins neuroscientist Paul Worley, …

Accurately predicting who’s at risk to develop Alzheimer’s disease may now be easier, Elizabeth Tracey reports Read more →

Proteins known as tau and beta amyloid have been part of the dialogue on Alzheimer’s disease development for many years, with methods to measure them and drugs to remove them active areas of research. Another protein involved in the process …

What can proteins in the blood and elsewhere teach us about developing dementia? Elizabeth Tracey reports Read more →